We initiate coverage of Oncodesign Precision Medicine (OPM), a French clinical-stage biopharmaceutical company, with a target valuation range of EUR 1.9-2.7. We consider the company a compelling investment opportunity for numerous reasons:1/ OPM-101: RIPK2 inhibitor for immune checkpoint inhibitor-associated colitis (ICI-AC) and inflammatory bowel diseases (IBDs)Compelling scientific rationale and (pre)clinical data, indicating safety, preliminary efficacy, and selectivity, support RIPK2 inhibit ....

17 Apr 2024
(Sponsored) Oncodesign Precision Medicine - Targeted therapies for inflammation & oncology

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
(Sponsored) Oncodesign Precision Medicine - Targeted therapies for inflammation & oncology
- Published:
17 Apr 2024 -
Author:
David Seynnaeve, PhD -
Pages:
61 -
We initiate coverage of Oncodesign Precision Medicine (OPM), a French clinical-stage biopharmaceutical company, with a target valuation range of EUR 1.9-2.7. We consider the company a compelling investment opportunity for numerous reasons:1/ OPM-101: RIPK2 inhibitor for immune checkpoint inhibitor-associated colitis (ICI-AC) and inflammatory bowel diseases (IBDs)Compelling scientific rationale and (pre)clinical data, indicating safety, preliminary efficacy, and selectivity, support RIPK2 inhibit ....